Antares Pharma, Inc. is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The company has market cap of $448.73 million. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. It currently has negative earnings. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.
Analysts expect ABB Ltd (ADR) (NYSE:ABB) to report $0.23 EPS on April, 19.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.23 EPS. ABB’s profit would be $511.35 million giving it 25.32 P/E if the $0.23 EPS is correct. After having $0.33 EPS previously, ABB Ltd (ADR)’s analysts see -30.30% EPS growth. The stock decreased 0.09% or $0.02 on April 7, reaching $23.29. About shares traded. ABB Ltd (ADR) (NYSE:ABB) has risen 5.53% since September 1, 2016 and is uptrending. It has underperformed by 2.98% the S&P500.
The stock decreased 1.35% or $0.04 on April 7, reaching $2.93. About shares traded. Antares Pharma Inc (NASDAQ:ATRS) has risen 142.15% since September 1, 2016 and is uptrending. It has outperformed by 133.64% the S&P500.
Armistice Capital Llc holds 6.06% of its portfolio in Antares Pharma Inc for 11.00 million shares. Broadfin Capital Llc owns 12.97 million shares or 3.36% of their US portfolio. Moreover, Jw Asset Management Llc has 1.69% invested in the company for 1.09 million shares. The Minnesota-based Perkins Capital Management Inc has invested 1.55% in the stock. Perceptive Advisors Llc, a New York-based fund reported 2.92 million shares.
Since January 1, 0001, it had 1 insider purchase, and 4 sales for $164,944 activity.
Analysts await Antares Pharma Inc (NASDAQ:ATRS) to report earnings on May, 8. They expect $-0.04 earnings per share, up 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.03 actual earnings per share reported by Antares Pharma Inc for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.
Among 14 analysts covering ABB Ltd (NYSE:ABB), 8 have Buy rating, 2 Sell and 4 Hold. Therefore 57% are positive. ABB Ltd had 24 analyst reports since August 21, 2015 according to SRatingsIntel. Jefferies maintained it with “Sell” rating and $18 target in Wednesday, April 5 report. The firm earned “Buy” rating on Tuesday, January 10 by Bank of America. The firm earned “Sell” rating on Friday, September 4 by Berenberg. The stock of ABB Ltd (ADR) (NYSE:ABB) has “Outperform” rating given on Friday, December 11 by RBC Capital Markets. UBS upgraded the shares of ABB in report on Friday, January 22 to “Neutral” rating. On Monday, December 12 the stock rating was upgraded by Robert W. Baird to “Outperform”. The firm has “Neutral” rating given on Wednesday, April 20 by JP Morgan. The stock of ABB Ltd (ADR) (NYSE:ABB) has “Hold” rating given on Friday, October 9 by Jefferies. Robert W. Baird maintained ABB Ltd (ADR) (NYSE:ABB) on Wednesday, October 5 with “Neutral” rating. The firm has “Overweight” rating given on Monday, December 12 by Morgan Stanley.
